These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15370011)

  • 41. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.
    Soyka M
    Expert Opin Drug Deliv; 2012 Nov; 9(11):1409-17. PubMed ID: 23013384
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia.
    Winstock AR; Lea T
    Subst Use Misuse; 2010; 45(1-2):240-52. PubMed ID: 20025451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.
    Orman JS; Keating GM
    Drugs; 2009; 69(5):577-607. PubMed ID: 19368419
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Buprenorphine in the treatment of opiate dependence.
    Wesson DR; Smith DE
    J Psychoactive Drugs; 2010 Jun; 42(2):161-75. PubMed ID: 20648912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of buprenorphine/naloxone in opioid-dependent humans.
    Stoller KB; Bigelow GE; Walsh SL; Strain EC
    Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment.
    Maremmani I; Gerra G
    Am J Addict; 2010; 19(6):557-68. PubMed ID: 20958853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction of patients with moderately severe methadone dependence onto buprenorphine.
    Glasper A; Reed LJ; de Wet CJ; Gossop M; Bearn J
    Addict Biol; 2005 Jun; 10(2):149-55. PubMed ID: 16191667
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
    Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
    Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Suboxone (buprenorphine/naloxone) as an agonist opioid treatment in Spain: a budgetary impact analysis.
    Martínez-Raga J; González Saiz F; Pascual C; Casado MA; Sabater Torres FJ
    Eur Addict Res; 2010; 16(1):31-42. PubMed ID: 19923837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post marketing surveillance of sublingual buprenorphine naloxone combination tablets.
    Ray R; Vaswani M; Deb KS; Sethi H; Chopra A; Kishore N; Goyal R
    Indian J Physiol Pharmacol; 2012; 56(4):359-66. PubMed ID: 23781656
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
    Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
    Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
    Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
    Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opioid dependence: rationale for and efficacy of existing and new treatments.
    Fiellin DA; Friedland GH; Gourevitch MN
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What is diversion of supervised buprenorphine and how common is it?
    Winstock AR; Lea T; Sheridan J
    J Addict Dis; 2009 Jul; 28(3):269-78. PubMed ID: 20155596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Buprenorphine replacement therapy: a confirmed benefit.
    Prescrire Int; 2006 Apr; 15(82):64-70. PubMed ID: 16604748
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
    Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
    Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Opioid plasma concentrations in methadone-and buprenorphine-maintained patients.
    Jagsch R; Gombas W; Schindler SD; Eder H; Moody DE; Fischer G
    Addict Biol; 2005 Dec; 10(4):365-71. PubMed ID: 16318959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.